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Abstract
It has been shown in various mammal species that clonidine, a
well known centrally acting hypotensive agent, acts through the
activation of imidazoline receptors (IRs) in the nucleus reticu-
laris lateralis (NRL) of the brainstem. Specific binding sites
sensitive to imidazolines and insensitive to catecholamines
have been detected in rat and bovine, as well as human brains.
An endogenous ligand, other than catecholamines, should exist
for these IRs. Such a ligand could play a role in the pathophysi-
ology of human essential hypertension. Therefore, we devel-
oped two RIAs with polyclonal and monoclonal anticlonidine
antibodies. These antibodies presented specificity spectra simi-
lar to that of the IRs: they bound imidazolines and not catechol-
amines at all. These RIAs were used to detect imidazoline-like
immunoreactivity in the human serum. Immunoreactive sub-
stance was measured in 26 normotensive subjects' sera, and
specificity of interaction between antibodies and sera was veri-
fied. None of the known endogenous substances tested so far
were able to interact with the two antibodies. Immunoreactivity
in 32 essential hypertensive patients' sera proved higher in
- 30% of cases. Values of immunoreactivity positively corre-
lated with the mean arterial pressure values. This study demon-
strates the existence of an "imidazoline-like" immunoreactive
substance in the human serum with high levels in some hyper-
tensive patients. (J. Clin. Invest. 1993. 92:1068-1072.) Key
words: imidazoline receptors * endogenous ligand * clonidine
immunoreactivity * radioimmunoassays
Introduction
Clonidine is a well known, centrally acting hypotensive sub-
stance that was described as an a2-adrenoceptor agonist. How-
ever, recently, animal investigations concerning the mecha-
nism of the hypotensive effect of clonidine have led to the
discovery of a new class of receptors: the imidazoline receptors
(IR).I The demonstration of the existence of these IRs and
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1. Abbreviations used in this paper: CDS, clonidine-displacing sub-
stance; IR, imidazoline receptor; ng pac eq, nanogram para-amino-
clonidine equivalent; NRL, nucleus reticularis lateralis; pac, para-
aminoclonidine.
their involvement in the central control ofblood pressure were
based on the following observations:
(a) in rats, clonidine hypotensive effect originates in the
nucleus reticularis lateralis region in the brainstem ( 1 );
(b) catecholamines stereotaxically injected into this region
never affected arterial pressure, in contrast with imidazolines,
-which were hypotensive whatever their selectivity for alpha-
adrenoceptor subtypes (2);
(c) in vivo electrochemical experiments performed in rats,
confirmed that the clonidine hypotensive effect originating in
the NRL region was related to imidazoline specific receptors
and that sedation, the main side effect of clonidine, was due to
activation of alpha2-adrenoceptors elsewhere in the brainstem,
namely, the locus coeruleus (3);
(d) binding experiments with [3H]clonidine and [3H]-
para-aminoclonidine (pac) also confirmed besides a classical
a2-adrenergic binding of these ligands, the existence of specific
imidazoline binding sites insensitive to catecholamines both in
the brain and in peripheral tissues of various species, including
humans, the hypotensive effect ofimidazolines being related to
the specific imidazoline binding (4-6);
(e) biochemical experiments( 7) permitted physical separa-
tion of alpha-adrenoceptors and imidazoline specific binding
sites leading to the conclusion that they should be considered as
two different molecular entities, at least within the rabbit
kidney.
As these IRs are present in the human brain (4), one could
assume that a noncatecholamine endogenous ligand could ex-
ist also in humans. And if IRs are involved in the regulation of
cardiovascular tone in humans as it is in animals, it could there-
fore also be assumed that a dysfunctioning ofthe "imidazoline
receptor system," concerning the receptor itself, or its endoge-
nous ligand or both, might be associated with certain forms of
essential hypertension. In fact, one could suppose that the en-
dogenous ligand of IRs may share certain structural analogies
with imidazolines. To test the presence ofendogenous imidazo-
line-like substances, we developed polyclonal and monoclonal
antibodies against clonidine with para-aminoclonidine (pac)
coupled to hemocyanine as the antigen (8, 9). As was the case
with IRs, these two antibodies bound imidazoline molecules
and not catecholamines at all.
We have reported elsewhere that these antibodies were able
to detect immunoreactive substances in bovine brain extracts
(polyclonal antibodies; reference 8) and in human brain ex-
tracts (monoclonal antibody mFE7; reference 9) containing
the putative endogenous ligand for IRs.
Here we compare two radioimmunoassays developed with
the polyclonal and monoclonal antiimidazolines antibodies to
detect circulating immunoreactive substances in human sera
from normotensive and hypertensive subjects.
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Methods
Antibody preparation. Preparation of polyclonal antibodies has been
described elsewhere (8). Briefly, para-aminoclonidine linked to hemo-
cyanin with glutaraldehyde was injected into rabbits. The resulting spe-
cific antisera were characterized: the polyclonal antibodies recognized
imidazolines closely related to clonidine and no known endogenous
substances tested.
Monoclonal antibody (mFE7) production and characterization
has been described elsewhere (9). Despite a lower affinity for free pac
and clonidine than the polyclonal antibodies, the specificity was simi-
lar: mFE7 recognized iminoimidazolidines and no catecholamines or
other known endogenous substances tested.
Subjects and patients. Essential hypertensive patients and normo-
tensive subjects were investigated in this study.
Serum (15-20 ml) from 26 normotensive subjects (19 males and 7
females; mean value ofage±SD = 40.7±17.4 yr, range: 20-79 yr) were
obtained from the local blood donor bank (Centre de Transfusion San-
guine, Strasbourg France) and from volunteers of the laborato-
ry. Blood pressure parameters were: systolic arterial pressure
= 116.9±13.0 mmHg, diastolic arterial pressure = 74.2±5.8 mmHg,
and mean arterial pressure = 88.5±6.8 mmHg. The series of sera from
hypertensive patients was provided by the Hypertension Unit of Brous-
sais Hospital, Paris. It included samples (3-10 ml) from 32 patients
with normal renal function (24 males and 8 females; mean value of
age±SD = 45.6±12.0, range 18-71 yr). No patients received any anti-
hypertensive drug, and 23 out of 32 received no other medication be-
fore study. The remaining nine were treated with anxiolytic drugs.
They all had normal plasma creatinine, potassium, aldosterone, renin
activity, and 24-h urinary normetanephrin and metanephrin; they
could therefore be classified as essential hypertensive patients. Urinary
normetanephrin and metanephrin were measured according to the
method described by Trouvin and Billaud-Mesguich (10) to avoid in-
clusion of patients with pheochromocytoma in our study. Blood pres-
sure parameters (mean±SD) were as follows: systolic arterial pressure;
156.3±17.8 mmHg; diastolic arterial pressure, 98.8±10.6 mmHg; and
mean arterial pressure, 118.0±11.4 mmHg. They were therefore desig-
nated as moderate hypertensive patients.
Sample preparation. All the samples tested in this study were pre-
pared without any blood-clotting inhibitors and after fasting (10 h). All
the sera were stored frozen at
-20°C until used (4-8 wk). Subse-
quently, sera were thawed and ultrafiltered through membranes
(YM1-MW cutoff, 1,000 D-level; Amicon Div., W. R. Grace, Inc.,
Beverly, MA) at 4°C. Membranes were washed with 10 ml ultrapure
water, and resulting dialysates lyophilized. The dry powder obtained
was methanol extracted three times with decreasing volumes ofmetha-
nol (4,2,1 ml; RCS 10-60; Jouan, Paris). The methanol soluble frac-
tions were evaporated to dryness in a speedvac, reconstituted in 5 ml of
ultrapure water, and stored at -20°C until analysis by radioimmunoas-
says described below.
Serum extracts were first tested with the monoclonal RIA. Thawed
serum extracts were kept at 4°C for 3 d to allow three separate analysis.
Sera extracts were frozen again and tested with the polyclonal RIA after
storing 1 mo at -20°C.
Radioimmunoassays. The radioimmunoassays developed either
with polyclonal or with monoclonal anticlonidine antibodies were simi-
lar, except for antibody dilution and for the quantities ofcold pac used
to obtain the standard curves (see below).
Assay medium constituted of 100 antibody (for polyclonal anti-
body, final dilution: 1/400; for monoclonal antibody, final dilution:
1/2,000) in Tris-HCl buffer, 50 mM, pH 7.2, 100 ,l Tris buffer zero
standard (BO) or known standard amount of cold pac or unknown
samples (B) and 20 Ml [3H]pac (10,000-15,000 dpm, specific activity:
50 Ci/mM; New England Nuclear, Boston, MA). Dilutions ofantibod-
ies were chosen so that 50% radioligand was bound in B0. Incubation
time was 2 h at room temperature. Separation of bound from free
ligand has been performed as previously described (8, 9).
A set ofstandard unlabeled pac samples was freshly prepared in the
following concentration range: stock solution of 10 mg/ml pac in Tris
buffer was diluted to obtain 0. 1, 0.25, 0.75, 1, 2.5, 5, 7.5, and I0 ng pac
in the assay for polyclonal antibodies, and 1, 5, 10, 20, 40, 60, 80, 100,
200, and 300 ng pac in the assay for the monoclonal antibody. These
standards were carried out through the RIA in triplicate. The radioactiv-
ity counted in the supernatants was used to calculate bound (B) [3H]-
pac for each point ofthe standard curves. These values were divided by
the count ofthe zero standard (BO) and the logit transformation plotted
vs. the natural logarithm, loge, of the amount of cold pac to construct
the calibration curves. Results of unknown samples were expressed in
arbitrary units as ng pac equivalent (ng pac eq) as determined by extrap-
olation ofcalibration curves and related to the initial volume ofserum.
Each determination was performed in triplicate, and each unknown
sample was tested at least at three dilutions in three independent exper-
iments. Nonspecific binding was measured in the presence of 100 tg
unlabeled pac in the assay.
Saturation experiments of monoclonal antibody mFE7 were
carried on in the absence and presence ofserum extracts. Isotopic dilu-
tions were used because ofthe intermediate affinity ofthis antibody for
free pac. Increasing amounts of cold pac (10 to 80 ng/ 100 1l) were
incubated with 100 gl serum extract, mFE7 antibody (100 Ml; final
dilution: 1/ 1,000) and 25 Ml of [3H]pac ( 1 nM) were then added. The
procedure described above was then used to measure bound radioactiv-
ity and the binding values obtained by computer analysis of data
by the program EBDA (Elsevier BIOSOFT Advanced Technology,
Cambridge, UK [11 ]).
Results
Sensitivity ofradioimmunoassays. Typical calibration curves,
generated according to the proposed protocol, are shown in
Fig. 1.
The RIA procedures appeared to be most suitable for the
detection of pac levels in the range from 0.25 to 10 ng/ 100 pl
for polyclonal antibodies and from 5 to 100 ng/ 100 gl for the
monoclonal antibody. Thus, the polyclonal RIA appeared
about ten times more sensitive than the monoclonal RIA, due
to the higher affinity of polyclonal antibodies for free pac
(Kd = 13 nM) compared to monoclonal antibodies (Kd
= 180 nM).
Immunoreactivity in the human samples. In the serum ex-
tracts of normotensive subjects, immunoreactivity was detect-
able at low level (Fig. 2, lines 1 and 3) with the two radioimmu-
noassays. Mean values (mean±SD) of immunoreactivity were
7.6±12.1 ng pac eq/ml (n = 26) with monoclonal antibodies
and 1 1.9±19.2 ng pac eq/ml (n = 26) with polyclonal antibod-
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Figure 1. Typical calibration curves expressed on a log-logit scale of
polyclonal and monoclonal RIA. Each point is the mean±SEM of
nine independent experiments effected in triplicates.
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Figure 2. Imidazoline-like immunoreactivity measured in serum ex-
tracts from normotensive (lines 1 and 3) and hypertensive (lines 2
and 4) subjects with monoclonal RIA (lines I and 2), and polyclonal
RIA (lines 3 and 4). Each point represents a different individual.
The results are expressed as ng pac eq/ml serum, calculated by ex-
trapolation of standard curves as described in Methods. Results are
the mean of at least three determinations at two dilutions of serum
extracts in triplicate.
ies. The ranges of values were respectively 0 to 48.7 ng pac
eq/ml and 0 to 74.3 ng pac eq/ml.
However, significant differences with these values were
noted in the hypertensive group. As can be seen in Fig. 2, lines
2 and 4, some higher immunoreactivity values were found in
this group. The mean value (mean±SD) with monoclonal RIA
was 58.5±106.4 ng pac eq/ml serum (n = 32, values range:
0-384). The polyclonal RIA assays gave a mean value of
77.9±77.6 ng pac eq/ml (n = 32, values range: 0-350). Con-
sidering a basal arbitrary upper limit of 50 ng pac eq/ml for
monoclonal RIA and of 100 ng pac eq/ml for polyclonal RIA
observed in the normotensive group, 25 and 28. 1% (with mono-
clonal and polyclonal RIAs, respectively) of the hypertensive
patients studied here showed high immunoreactivity values.
Interestingly, none ofthese patients was treated with anxiolytic
drugs.
Monoclonal mFE7 and rabbit polyclonal anti-para-amino-
clonidine antibodies gave similar qualitative and quantitative
results, as the values obtained with both correlated very well (r
=0.78,P<0.0l,n= 58).
Specificity ofthe interaction between immunoreactive sub-
stance and the antibodies. Parameters of pac standard curves
and serum sample dilution curves were compared. Dilution of
the extracted samples yielded curves with slopes identical to the
pac standard curve (Fig. 3). We can thus assume that homolo-
gous interactions occur between antibodies and pac, and anti-
bodies and immunoreactive substances. In addition, analysis
with monoclonal RIA of immunoreactivity present in human
serum extracts supplemented with pac at concentrations from
10 to 80 ng/assay demonstrated additivity of reactivity of pac
and imidazoline-like immunoreactivity. Scatchard analysis of
saturation data in the absence and the presence of serum ex-
tracts led to the following results. The Kd value decreased in the
presence of serum extract: 168±44 nM vs. 599±190 nM
(mean±SEM, n = 5, P < 0.05) and the Bm. value remained
unchanged with 3.98±0.74 vs. 3.72±0.93 nmol/mg protein.
Serum extracts behave as competitive inhibitors ofpac binding
on the antibody.
Figure 3. RIA response curves (log-logit scale) based on serial dilu-
tions ofpac (o ) and ofserum extracts (e, A). Representative experi-
ments of two different extracts, each point tested in triplicate. Curve
equations were: y = -l.07x - 1.26 for serum A; y = -1.05x - 1.81
for serum B; y = -0.98x + 2.9 for pac.
Endogenous constituents of serum are known to provoke
nonspecific interference in antigen-antibody interaction. We
therefore studied the possible influence of urea in our radioim-
munoassays. This substance appeared to have no effect in our
assays up to a concentration of 1 mM. No correlation between
urea concentration in the serum extracts tested and the level of
immunoreactivity was found, even when assuming a 100% re-
covery of serum urea after sample preparation steps.
Relationships between blood pressure parameters and im-
munoreactivity. To test the involvement of the immunoreac-
tive substance in hypertensive pathogenesis, we examined the
possible relationships between mean arterial pressure and the
values of immunoreactivity obtained with the two RIAs. Indi-
vidual values of the imidazoline-like immunoreactivity corre-
lated positively with the mean arterial pressure values, r
= 0.554, P < 0.01 for polyclonal RIA (Fig. 4) and r = 0.39, P
< 0.01 for monoclonal RIA.
Heart rates ofpatients with high levels ofimmunoreactivity
were not significantly different (P = 0.54) from those with low
levels: 69.1±11.0 beats/min (mean±SD, n = 9) and 71.4±9.3
beats/min (mean+SD, n = 23), respectively.
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Figure 4. Relationships between imidazoline-like immunoreactivity
(measured with polyclonal antibodies) and mean arterial pressure.
Correlation coefficients were calculated from linear regression by the
least-squares method.
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Discussion
Antibodies raised against therapeutic agents have generally
been used in bioavailability and pharmacokinetic studies, in
addition to therapeutic drug monitoring in patients. Several
RIAs with clonidine-specific polyclonal antibodies have been
developed for these purposes ( 12-15). Assays with these anti-
bodies were conducted as usually described for drug-specific
RIAs: (a) accuracy was determined with biological fluids
(serum, urine) with added known levels of drugs; (b) so-called
"matrix effects" were abolished in the assays by dilutions of
analytical samples in biological fluids identical to those used
for calibration curves, except that they were drug free; (c) speci-
ficity ofRIAs was generally assessed by determining cross-reac-
tivities of drug metabolites; (d) pharmacokinetics in human
plasma were studied after oral or intravenous administration of
clonidine. In contrast, data presented in this paper only con-
cern clonidine- or clonidine-like drug-free subjects, and thus
concern clonidine-free serum samples. Even in the absence of
clonidine and clonidine-like drugs, both polyclonal and mono-
clonal anticlonidine antibodies detected immunoreactivity in
human serum.
What is the nature of the substances responsible for this
immunoreactivity? Several criteria have been tested to assess
the specificity of the interaction between fluid extracts and the
antibodies. Linearity of results obtained with serial dilutions of
samples, as well as parallelism observed between standard
curves and sample curves, showed that the interactions of pac
and endogenous substance with antibodies are similar. In addi-
tion, serum extracts that have been supplemented with pac
gave a curve that was superimposable on the pac standard
curve when corrected for endogenous immunoreactivity. De-
spite slightly different specificity spectra, the two different anti-
bodies gave the same qualitative and quantitative results. As
the material used in this study was oflimited purity, we cannot
exclude the possibility that known biological substances are
recognized by the antibodies. Therefore, to determine specific-
ity spectra of our two antibodies, we focused our attention on
endogenous substances present in human serum and poten-
tially capable ofinteracting with pac binding on the antibodies.
As shown elsewhere (8), catecholamines (noradrenaline,
adrenaline, dopamine) and their metabolites (DOPAC, DO-
PEG, dihydroxymandelic acid) as well as histamine, purine,
adenine, and adenosine were unable to cross-react with polyclo-
nal antibodies. We recently completed that list with arginine,
guanidine, guanosine, carnosine, histidine, and tyrosine that
all were ineffective on pac binding on the antibodies. Similarly,
monoclonal antibody mFE7 specificity has been reported else-
where (9) and showed the same results. All known endogenous
substances we have so far tested with the two antibodies ap-
peared without effect in the RIA described here.
Certain causes of false positive results due to nonspecific
interactions could also be ruled out. Arndts et al. ( 1 3) attrib-
uted the erroneous blank values they obtained with a clonidine
RIA to matrix effects. The dilution of plasma samples in nor-
mal human plasma was sufficient to abolish these effects. In
our case, we tested immunoreactivity in serum extracts devoid
of proteins and salts. Ultrapure water was used to reconstitute
the samples and Tris buffer was the diluent for both standard
and samples curves. In addition, dilutions of samples did not
abolish the immunoreactivity.
Naturally occurring substances such as urea are known to
inhibit antigen-antibody interactions. We were unable to find
any correlation between urea concentration in the blood sam-
ple extracts and immunoreactivity levels. Drugs or metabolites
could also interfere with RIA. For example, Farina et al. ( 12)
demonstrated that salicylic acid decreased the sensitivity ofan
immunological assay of clonidine. Our first group of sera was
provided by healthy normotensive donors. Despite the fact that
they received no medication, a basal level ofimmunoreactivity
was observed with both antibodies. None of the hypertensive
patients received any antihypertensive treatment. Associated
treatments consisted essentially ofbenzodiazepine anxiolytics,
and no drugs had structural analogies with imidazolines. We
have at the present time no evidence that immunoreactivity
observed in the serum could be attributed to nonspecific inter-
action in the RIAs.
The chemical nature of the substance present in the serum
is, for the moment, unknown, but some indications can be
drawn from the method of preparation of serum extracts. The
immunoreactive substance appears not to be a protein: it has a
molecular mass < 1,000 D, it is methanol- and water-soluble,
and its structure must be related to that of clonidine or para-
aminoclonidine according to the strict specificity of the anti-
bodies used in this study.
The plasma level ofthe imidazoline-like immunoreactivity
was much higher in some patients with essential hypertension
receiving no antihypertensive treatment. The immunoreactiv-
ity could reach levels as high as ten times the values observed in
normotensive subjects. High levels ofthe immunoreactive sub-
stance were observed in - 30% of the hypertensive patients.
One can assume that, since some borderline hypertensives
were included in the group of hypertensive patients, this per-
centage was even underestimated.
We did not observe differences between heart rate values
among the groups of patients whether they exhibited high or
low immunoreactivities. These results seem to indicate that the
autonomic nervous system activities in both groups ofpatients
were similar. The correlation between mean arterial pressure
and immunoreactivity is particularly interesting; an abnormal
high serum level ofthis substance might therefore be associated
with certain forms of the so-called essential hypertension. The
presence of high serum level of clonidine-like substances has
also been described in pregnancy-induced hypertension ( 16).
The question remains whether the immunoreactive sub-
stance detected with anticlonidine antibodies and the putative
endogenous ligand for IRs are identical. Indirect evidences ar-
gue in favor of this hypothesis. (a) Specificities ofour antibod-
ies are limited to imidazoline-containing substances; (b) the
two antibodies we used proved capable to detect immunoreac-
tivity in bovine and human brain extracts containing the puta-
tive endogenous ligand of IRs; (c) an immunoreactive com-
pound supposed to be aCDS (clonidine-displacing substance)-
like substance was detected with polyclonal anticlonidine
antibodies in rat serum extracts and proved able to contract rat
gastric fundus smooth muscle (17); (d) Synetos et al. (18)
reported the presence ofCDS, supposed to contain the endoge-
nous ligand of IRs, in human serum. Only the purification of
both the endogenous ligand to IRs and the imidazoline-like
immunoreactive circulating substance will provide an unequiv-
ocal proof of their identity.
Biological effects of CDS, related to vasomotor tone, have
been described: it proved hypertensive in animal models ( 19)
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and contracted blood vessels in a dose-dependent man-
ner (18).
Thus, if the substance we detected with higher circulating
levels in some hypertensive patients is related to CDS, then this
one might contribute to maintain an elevated arterial pressure
and clonidine-like drugs might therefore be antihypertensive
through inhibition ofthe CDS effects. Again, the complete puri-
fication of these compounds will clarify this point.
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